BIOMAT Database Logo BIOMAT Database Logo

Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. 1994

M Baba, and S Shigeta, and S Yuasa, and H Takashima, and K Sekiya, and M Ubasawa, and H Tanaka, and T Miyasaka, and R T Walker, and E De Clercq
Department of Microbiology, Fukushima Medical College, Japan.

MKC-442 (6-benzyl-1-ethoxymethyl-5-isopropyluracil or I-EBU) has recently been identified as a highly potent and specific inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. Since the compound has favorable pharmacokinetic and toxicity profiles in vivo, we have evaluated MKC-442 for its inhibitory effect on the replication of HIV-1 in various cell cultures, including human peripheral blood lymphocytes and monocyte-macrophages. The 50 and 90% effective concentrations for HIV-1 (HTLV-IIIB strain) replication in MT-4 cells were 15 and 98 nM, respectively. MKC-442 was also inhibitory to HIV-1 replication in peripheral blood lymphocytes and monocyte-macrophages as determined by the production of p24 antigens in the culture supernatant. Fluorescence-activated cell sorter analysis revealed that MKC-442 was equally active against zidovudine-resistant mutants and zidovudine-susceptible strains. Furthermore, combinations of MKC-442 with either 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, or 2',3'-dideoxyinosine synergistically inhibited the replication of HIV-1. Thus, MKC-442 has been considered as a candidate for clinical efficacy studies.

UI MeSH Term Description Entries
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

M Baba, and S Shigeta, and S Yuasa, and H Takashima, and K Sekiya, and M Ubasawa, and H Tanaka, and T Miyasaka, and R T Walker, and E De Clercq
Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
October 1993, Molecular pharmacology,
M Baba, and S Shigeta, and S Yuasa, and H Takashima, and K Sekiya, and M Ubasawa, and H Tanaka, and T Miyasaka, and R T Walker, and E De Clercq
The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
March 1995, Antiviral research,
M Baba, and S Shigeta, and S Yuasa, and H Takashima, and K Sekiya, and M Ubasawa, and H Tanaka, and T Miyasaka, and R T Walker, and E De Clercq
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
April 1992, Antimicrobial agents and chemotherapy,
M Baba, and S Shigeta, and S Yuasa, and H Takashima, and K Sekiya, and M Ubasawa, and H Tanaka, and T Miyasaka, and R T Walker, and E De Clercq
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
March 2009, Antimicrobial agents and chemotherapy,
M Baba, and S Shigeta, and S Yuasa, and H Takashima, and K Sekiya, and M Ubasawa, and H Tanaka, and T Miyasaka, and R T Walker, and E De Clercq
U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.
May 1993, Antimicrobial agents and chemotherapy,
M Baba, and S Shigeta, and S Yuasa, and H Takashima, and K Sekiya, and M Ubasawa, and H Tanaka, and T Miyasaka, and R T Walker, and E De Clercq
(s4dU)35: a novel, highly potent oligonucleotide inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.
October 1996, FEBS letters,
M Baba, and S Shigeta, and S Yuasa, and H Takashima, and K Sekiya, and M Ubasawa, and H Tanaka, and T Miyasaka, and R T Walker, and E De Clercq
Synthesis of novel MKC-442 analogues with potent activities against HIV-1.
July 2003, Archiv der Pharmazie,
M Baba, and S Shigeta, and S Yuasa, and H Takashima, and K Sekiya, and M Ubasawa, and H Tanaka, and T Miyasaka, and R T Walker, and E De Clercq
A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
January 2017, Journal of virology,
M Baba, and S Shigeta, and S Yuasa, and H Takashima, and K Sekiya, and M Ubasawa, and H Tanaka, and T Miyasaka, and R T Walker, and E De Clercq
Thiamine disulfide as a potent inhibitor of human immunodeficiency virus (type-1) production.
November 1994, Biochemical and biophysical research communications,
M Baba, and S Shigeta, and S Yuasa, and H Takashima, and K Sekiya, and M Ubasawa, and H Tanaka, and T Miyasaka, and R T Walker, and E De Clercq
Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.
October 1995, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!